AstraZeneca Will Collect Longer-Term Safety Data For Seroquel XR
Executive Summary
AstraZeneca is committed to new studies and could modify ongoing observational studies to collect data on the long-term safety issues that troubled an FDA advisory panel during its consideration of Seroquel XR (quetiapine) for treating major depressive disorder and generalized anxiety disorder